Strongbridge Biopharma plc
900 Northbrook Drive1
Suite 200
Trevose, PA 19053
(610) 254-9022
February 1, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Joseph McCann
Re: | Strongbridge Biopharma plc— Request for Acceleration |
| Registration Statement on Form F-3 |
| File No. 333- 215531 |
Dear Mr. McCann:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Strongbridge Biopharma plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333- 215531) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Standard Time on February 2, 2017, or as soon thereafter as practicable.
The Registrant hereby authorizes each of Aron Izower, Esq. and Wendy Grasso, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Aron Izower at (212) 549-0393 or, in his absence, Wendy Grasso at (212) 549-0216.
| STRONGBRIDGE BIOPHARMA PLC | |
|
| |
|
| |
| /s/ Matthew Pauls | |
| By: | Matthew Pauls |
|
| Chief Executive Officer |